Transglutaminase-Catalyzed Crosslinking in Neurological Disease: From Experimental Evidence to Therapeutic Inhibition

Author(s): G. Hoffner, W. Andre, A. Vanhoutteghem, S. Soues, P. Djian

Journal Name: CNS & Neurological Disorders - Drug Targets
(Formerly Current Drug Targets - CNS & Neurological Disorders)

Volume 9 , Issue 2 , 2010

Become EABM
Become Reviewer


Diseases of polyglutamine expansion, Alzheimers disease and Parkinsons disease are neurodegenerative diseases associated with insoluble protein aggregates and neuronal death. These diseases constitute a group of devastating diseases for which there is currently little treatment. The protein aggregates may be the cause of neuronal death, although there is some controversy as to which form of aggregation (oligomers, polymers or microscopic aggregates) is the most toxic. More than a decade ago, the participation of transglutaminases in the formation of the abnormal protein aggregates was proposed. Transglutaminases are a large family of enzymes that catalyze the formation of Nε(γ-glutamyl)-lysine isodipeptide crosslinks between proteins. In this review, we summarize the evidence supporting the participation of transglutaminase in diseases of the central nervous system. We also describe newly developed transglutaminase inhibitors and their potential use as therapeutic agents in neurological disease.

Keywords: Polyglutamine, Alzheimer, Parkinson, protein aggregation, neuronal inclusions

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2010
Page: [217 - 231]
Pages: 15
DOI: 10.2174/187152710791012107
Price: $65

Article Metrics

PDF: 5